Three immunotherapy drugs approved for the treatment of melanoma may be used to treat advanced lung, liver, head and neck, and colorectal cancers, according to clinical trial results presented at the 2015 American Society of Clinical Oncology annual meeting in Chicago.
The NCI-MATCH phase II study is intended to allow the institute and its clinical trials groups catapult to the premier role in cancer research.
ECOG-ACRIN Cancer Research Group is starting enrollment in NCI-MATCH, the most ambitious of NCI's new generation of clinical trials.
The Conquer Cancer Foundation of the American Society of Clinical Oncology announced the recipients of the 2015 Young Investigator Awards, Career Development Awards, Advanced Clinical Research Award in Breast Cancer, and the Comparative Effectiveness Research Professorship in Breast Cancer.
The U.S. Court of Appeals for the D.C. Circuit Court upheld on May 22 a lower court's order requiring nine tobacco companies to publish “corrective statements” about the dangers of tobacco and its practices of marketing to children.
The Federal Bureau of Investigation is reportedly trying to establish whether Johnson & Johnson—one of the largest manufacturers of power morcellators—knew as early as nine years ago that the gynecological device can disseminate uterine cancers.
By 1986, there were substantial data in animals that molecularly-clone human haematopoietic growth factors, such as granulocyte-macrophage colony stimulating factor (GM-CSF), could accelerate bone marrow recovery and increase survival after exposure to high-dose ionizing radiations given under controlled experimental conditions.
Neupogen, a drug widely used in oncology, recently received an FDA approval for boosting survival in people acutely exposed to myelosuppressive doses of radiation, also known as hematopoietic syndrome or acute radiation syndrome.
The Cancer Prevention and Research Institute of Texas awarded 28 grants through its academic research program, 11 grants through its prevention program and two grants through its product development research program.
FDA notified more than 300 medical practices that they may have purchased unapproved prescription drugs or injectable devices from a foreign supplier, Gallant Pharmaceutical International.
